Also known as Mounjaro, Zepbound
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Mounjaro and Zepbound are example U.S. products with different labeled uses. Prescribing information is the source of record for indications, warnings, and administration.
Tirzepatide is a single peptide engineered to activate two incretin-family receptors: GIP and GLP-1.
It is an approved prescription medicine in defined products. Informal 'research peptide' framing does not match its regulatory status as a licensed drug.
Mounjaro and Zepbound both contain tirzepatide but are labeled for different uses. They should not be treated as identical consumer products.
Tirzepatide is built to turn on two gut-hormone receptors at once: GIP and GLP-1. Together those pathways influence insulin, glucagon, appetite, and related metabolic signals. The medicine is long-acting and used as a once-weekly injection in approved products.
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist. GIP and GLP-1 receptors are class B GPCRs expressed on pancreatic islets and other tissues. Combined agonism is the intended pharmacologic distinction from single GLP-1 receptor agonists. Weekly pharmacokinetics are described in labeling. Mechanistic details beyond the PI are not required to understand labeled use.
Step 1
Peptide
Tirzepatide
Step 2
Targets
GIP receptor and GLP-1 receptor
Step 3
Pathway
Incretin signaling affecting insulin, glucagon, and energy-balance circuits
Step 4
Observed in research/labeling
Glycemic control (Mounjaro) and indicated weight-related uses (Zepbound), per current labels
Mounjaro is labeled as an adjunct to diet and exercise to improve glycemic control in indicated patients with type 2 diabetes. Current PI also describes pediatric extension to age 10 years and older; verify the live label.
Zepbound labeling covers chronic weight management in indicated adults and has additional labeled uses that should be confirmed on DailyMed rather than assumed from news headlines.
Large phase 3 programs (for example SURPASS and SURMOUNT) support labeled metabolic uses. Additional labeled uses may exist; confirm current DailyMed or manufacturer PI.
Rodent thyroid C-cell tumors are described in labeling. Human relevance has not been determined, per the PI.
2021 · Human clinical trial
Population: Adults with type 2 diabetes
Objective: Compare glycemic and related outcomes with tirzepatide versus semaglutide 1 mg once weekly.
Main finding: The trial reported greater reductions in glycated hemoglobin with tirzepatide than with the semaglutide comparator used in the study. Cross-trial or off-label comparisons should not be inferred.
Limitations: Comparator dose, open-label or design features as reported in the paper, and population limits apply. Not a ranking of all peptides.
2022 · Human clinical trial
Population: Adults with obesity, or overweight with a weight-related complication, without diabetes
Objective: Evaluate weight-change outcomes with tirzepatide versus placebo plus lifestyle intervention.
Main finding: The trial reported substantially greater mean weight reduction with tirzepatide than placebo in the studied population.
Limitations: Results apply to the trial regimen and population. Safety and indication details are defined in prescribing information, not this summary.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice. Follow the product PI for boxed warnings, GI warnings, and contraindications.
Long-term safety: Phase 3 programs and post-marketing experience exist for approved products. Residual uncertainty remains, especially off-label.
Evidence limitations: Headlines comparing 'best' incretin medicines oversimplify trial designs and labeled uses.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Approved prescribing information
Start/escalation schedules, maximum doses, and device sharing warnings are in the Mounjaro and Zepbound prescribing information. This site does not calculate a personal dose.
Discovery
complete
Dual incretin receptor agonist design.
Preclinical research
complete
Includes thyroid C-cell findings in rodents described in PI.
Human studies
complete
SURPASS and SURMOUNT programs.
Clinical trials
complete · 2021–2022+
Pivotal metabolic trials published in major journals.
Regulatory status
complete · 2022
Initial U.S. approval 2022; additional labeled uses thereafter.
A dual GIP and GLP-1 receptor agonist sold as FDA-approved products such as Mounjaro and Zepbound.
Product-specific uses include type 2 diabetes glycemic control (Mounjaro) and indicated weight-related uses (Zepbound). Confirm the current label.
It activates GIP and GLP-1 receptors involved in incretin and energy-balance signaling.
Yes, as specific prescription products beginning with U.S. approval in 2022.
Boxed thyroid C-cell warning, gastrointestinal effects, and other PI warnings. This page is not a complete safety list.
Metabolic Research
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
View peptide →